Skip to content
    ROP
    Earnings call· Mar 2025(Q1 FY25)

    ROPER TECHNOLOGIES INC ROP

    Apr 28, 2025 Source

    Executive summary

    Roper Technologies Q1 FY25 — Solid Start, CentralReach Acquisition, and Raised Full-Year Guidance

    Roper Technologies delivered a solid Q1 FY25, marked by expected organic growth and strong total revenue expansion, bolstered by strategic acquisitions. The company successfully integrated CentralReach, a high-growth software leader, and raised its full-year guidance despite absorbing acquisition-related dilution. Management emphasized the durable nature of its business model and its robust capital deployment capacity, actively pursuing a strong M&A pipeline in an uncertain macroeconomic environment.

    Highlights

    5

    • Q1 total revenue grew 12% and organic revenue grew 5%, meeting expectations.

    • Cash flow grew 12% over the last 12 months, demonstrating business durability.

    • Successfully completed the acquisition of CentralReach for $1.65 billion (net of $200 million tax benefit), expected to add $175 million revenue and $75 million EBITDA for TTM ending June 2026, growing ~20%.

    • Full-year total revenue guidance raised to the 12% area, and full-year DEPS guidance increased by $0.05 to $19.80-$20.05.

    • Application Software segment organic revenue grew 6% with core margins improving 110 basis points.

    Concerns

    4

    • Q1 free cash flow was $507 million, down 1% versus prior year, impacted by a $24 million legal settlement and bond coupon payments.

    • Reported EBITDA margin declined 90 basis points year-over-year to 39.3% due to acquisition mix, particularly Transact's lowest margin Q1.

    • Deltek's organic growth rate was reduced by 1-2 points for the full year due to uncertainty in government contracting (DOGE, budget).

    • Tariff exposure, primarily in the Technology Products segment, is expected to be a $10 million to $15 million issue, though largely mitigated by USMCA compliance.

    Guidance & targets

    11
    CategoryTargetConfidence
    Full-year total revenue growth
    12% area
    high materiality
    High
    Full-year organic growth rate
    6% to 7%
    high materiality
    High
    Full-year DEPS
    $19.80 to $20.05
    high materiality
    High
    Full-year effective tax rate
    21% to 22% area
    medium materiality
    High
    Q2 adjusted DEPS
    $4.80 to $4.84
    high materiality
    High
    CentralReach TTM revenue
    $175M
    medium materiality
    High
    CentralReach TTM EBITDA
    $75M
    medium materiality
    High
    CentralReach organic revenue and EBITDA growth
    20% area or a touch higher
    medium materiality
    High
    Application Software organic growth
    mid-single plus range
    medium materiality
    High
    Network Software organic growth
    mid-singles range
    medium materiality
    High
    Technology Products revenue growth
    high single-digit revenue growth
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    Application Software
    This segment continues to demonstrate resilience and deliver on growth expectations. Deltek grew in the mid-singles range, with strong cloud migration. Aderant had record Q1 bookings and strong cloud activity. PowerPlan saw recurring revenue growth and strong SaaS migration. Vertafore showed consistent ARR growth and strong customer retention. Procare is increasing market share. Transact and CBORD integration is on track.
    Organic revenue growth: 6%Core EBITDA margin improvement: 110 bps
    		—19%—41.4%
    Network Software
    Organic revenue grew as expected, given difficult prior year comps at MHA. DAT grew based on increased ARPU, product packaging, and cross-sell. Foundry declined due to prior strikes but showed 'green shoot' activity and is expected to return to growth. ConstructConnect was strong with customer bookings and improved retention. SoftWriters and SHP continue to grow nicely.
    		—1%—55.3%
    Technology Products
    Solid results. Verathon grew nicely, driven by BFlex and GlideScope leadership, with new product releases slated. Neptune was solid, completing a strategic acquisition of a cloud-based utility billing software. CIVCO declined due to a difficult prior-year comp. NDI performed well, winning in orthopedic surgery, interventional radiology, and cardiac ablation. Verathon and Neptune order momentum improved as the quarter progressed.
    Organic revenue growth: 6%
    		—6%—36.2%

    Operational metrics

    17
    Cash flow growth
    12%
    last 12 months

    Reflects the durability of the business model.

    EBITDA
    $740Mup 9% total, nearly 10% segment
    Q1 FY25

    Total and segment EBITDA growth.

    Reported EBITDA margin
    39.3%down 90 bps versus prior year
    Q1 FY25

    Impacted by acquisition mix.

    Core EBITDA margin
    4.8%up 50 bps
    Q1 FY25

    Excluding acquisitions.

    Diluted EPS
    $4.78above guidance range
    Q1 FY25

    Above guidance range of $4.70.

    Legal settlement impact on FCF
    $24M
    Q1 FY25

    Funded in January.

    Bond coupon payment impact on FCF
    $70M or 80 bps
    FY25

    First coupon payments in February and April for bonds issued in Q3 2024.

    Net debt to EBITDA
    2.4x
    Q1 FY25

    Finished the quarter with a fully undrawn revolver.

    Pro forma net debt to EBITDA
    3x
    Q1 FY25

    After funding CentralReach acquisition with revolver.

    Available capital deployment firepower
    $5B+
    next 12 months

    Remaining capacity for high-quality acquisitions.

    US revenue concentration
    85%
    Q1 FY25

    Over 85% of revenues generated in the U.S.

    Software revenue recurring
    85%
    Q1 FY25

    Over 85% of software revenues recur.

    CentralReach professionals using platform
    200,000
    daily

    Daily users of CentralReach's platform.

    ABA therapy demand (US)
    900M hours
    annual

    Current annual demand for ABA therapy in the U.S.

    ABA therapist supply (US)
    300M hours
    annual

    Current annual therapist hours supplied in the U.S.

    Tariff impact
    $10M to $15M
    FY25

    Estimated tariff impact, largely mitigated by USMCA compliance.

    Deltek organic growth rate reduction
    1 to 2 points
    FY25

    Reduction due to government contracting uncertainty.

    Industry KPIs

    8
    MetricValueDetails
    Revenue growth$1.9BUSD
    Arr net new arrmid-singles range%
    Bookings billingslow single digits%
    Large deal new logo metricsrecord
    Gross retention renewal rate95%%
    Operating FCF margin rule of 4039.3%%
    Ai product adoption monetizationnew
    Net revenue net dollar retention115% to 120%%

    Orderbook & backlog

    4
    Enterprise software bookingslow single digitsQ1 FY25

    up

    Expected following very strong Q4 performance; pipelines remain healthy.

    Bookings activitylow double digitsTTM

    up

    Trailing 12 months bookings activity, takes time to work into revenue.

    Aderant bookingsrecordQ1 FY25

    Record first quarter bookings.

    ConstructConnect customer bookings activitystrongQ1 FY25

    Fueled growth in the quarter.

    Product announcements

    3
    ProductTypeDetails
    Verathon new productsroadmap
    ConstructConnect GenAI productsroadmap
    CentralReach AI productslaunch

    Deals & partnerships

    3
    CentralReachAcquisition of market-leading cloud-native software solution for ABA therapy providers.$1.65B net of $200M tax benefit

    CentralReach enables ABA therapy providers to deliver care for individuals with autism spectrum disorder, used by ~200,000 professionals daily. Meets Roper's acquisition criteria for niche market leadership, customer intimacy, strong gross margins, high cash flow, and higher growth (20% area).

    Cloud-based utility billing software solutionAcquisition of a cloud-based utility billing software solution for Neptune.

    This acquisition provides Neptune with the final piece of its strategy to close the loop in the meter-to-cash cycle, fully connecting water meter read to data management, billing, and collection processes.

    Trucker ToolsBolt-on acquisition for DAT.

    DAT did a great job integrating the recent Trucker Tools bolt-on acquisition.

    Risks & headwinds

    5
    Government contracting uncertainty (Deltek)FY25

    1-2 points reduction in Deltek's organic growth rate for FY25

    Mitigation: Management views this as a short-term speed bump, not a structural issue, given the essential services provided by government contractors. Customer sentiment is 'quite good'.

    Tariff impactFY25

    $10M-$15M issue

    Mitigation: Most cross-border flows are USMCA compliant, mitigating most of the impact. Teams are actively working to countermeasure risks and rework supply chain activity.

    Q1 Free Cash Flow declineQ1 FY25

    Down 1% YoY to $507M

    Mitigation: Impacted by a $24M legal settlement and timing of bond coupon payments (first ones due in Feb/Apr). Expected to be more back-end weighted for the year, with strong Q3 performance from Transact and Frontline.

    Reported EBITDA margin declineQ1 FY25

    Down 90 bps YoY to 39.3%

    Mitigation: Primarily due to acquisition mix, as Transact's Q1 is its lowest margin quarter. Acquisition margins are expected to improve throughout the year, and core EBITDA margins expanded 50 bps.

    Macroeconomic uncertainty

    Discussed, not quantified

    Mitigation: Roper's durable business model (85%+ recurring software revenue, 95% gross retention, 30%+ FCF conversion) is well-suited to withstand uncertainty. Management is cautiously optimistic and actively pursuing M&A opportunities.

    What to watch in Q2 FY25

    5

    Deltek Organic Growth

    Next quarter / FY25
    CurrentReduced by 1-2 points for FY25
    TargetImprovement as government contracting uncertainty eases

    Why it matters

    Deltek is a significant software business, and its growth trajectory is impacted by external factors. Recovery would signal easing macro headwinds🌐.

    Deltek will grow this year, but we probably will take a point -- or we have taken a point or 2 of growth off the Deltek's organic growth rate for this year given the uncertainty.

    Q&A highlights

    8

    What are you seeing in the private equity market regarding deal activity and hesitancy?

    Neil Hunn acknowledged a general slowdown due to macro uncertainty but stated Roper's pipeline remains robust. He noted that many PE sponsors need to return capital, creating a favorable environment for Roper, and historically, times of uncertainty have presented unique deployment opportunities.

    “But what we're seeing on the ground with our pipeline, with our conversations with sponsors, investment bankers, companies is just a consistent drumbeat of activity. The pipeline is as robust as it's been.”

    asked by Brent Thill · answered by Neil Hunn

    2 min read5 chapters

    Detailed Narrative

    01

    CentralReach Acquisition and Strategic Rationale

    Roper successfully acquired CentralReach for $1.65 billion, net of a $200 million tax benefit. CentralReach is a market-leading cloud-native software solution for Applied Behavior Analysis (ABA) therapy providers, serving approximately 200,000 professionals daily. The acquisition aligns with Roper's criteria for niche market leaders with strong gross margins and high cash flow conversion, and meets the 'maturing leader' criteria with expected revenue and EBITDA growth in the 20% area. The business addresses a persistent shortage of ABA therapists, with current demand at 900 million hours versus 300 million supplied, and benefits from industry consolidation and mission-critical solutions.

    02

    Business Model Durability and Capital Deployment

    Roper emphasized the durability of its business model, with over 85% of revenues generated in the U.S. and over 85% of software revenues recurring. The company boasts a 95% gross retention rate and converts over 30% of revenue to free cash flow. Despite macroeconomic uncertainties, Roper remains well-positioned for capital deployment with over $5 billion in available firepower over the next 12 months. Management noted that times of uncertainty often present unique opportunities for strategic acquisitions, citing a robust pipeline of 'maturing leader' businesses.

    03

    Segment Performance Highlights

    The Application Software segment grew 19% total and 6% organically, with core EBITDA margins up 110 basis points. Key performers included Aderant with record bookings and strong cloud migration, and PowerPlan with growing recurring revenue and successful new product launches. The Network Software segment grew 1% organically as expected, with DAT benefiting from ARPU increases and Foundry showing 'green shoots' towards returning to growth. Technology Products grew 6% organically, driven by Verathon's product leadership and Neptune's strategic acquisition of a utility billing software solution.

    04

    Macroeconomic Headwinds and Mitigations

    Roper acknowledged macroeconomic uncertainties, specifically impacting Deltek's government contracting business. Deltek's organic growth was reduced by 1-2 points due to factors like DOGE, budget uncertainty, and potential government shutdowns, causing pipelines to 'push to the right.' The Technology Products segment also faces a $10 million to $15 million tariff impact🌐, though most cross-border flows are USMCA compliant, and teams are actively mitigating risks through supply chain adjustments. Management expressed confidence in the short-term nature of these headwinds.

    05

    Leadership Transitions and AI Integration

    Roper announced leadership changes, with Rafi Shure promoted to CEO of PowerPlan and Joe Gomes moving to lead Procare. The company is actively integrating AI across its portfolio, with CentralReach leading the way with new AI-powered solutions, though AI-driven revenue is not yet material. Roper is focused on extending its software with 'agentic capabilities' into customer workflows, expecting to monetize these on a 'work completed basis' and viewing AI as a significant TAM expander.

    AI-generated summary of the company’s earnings call. Not investment advice.